Unknown

Dataset Information

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.


ABSTRACT:

Objectives

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, and type I interferon plays an important role in its pathogenesis. Anifrolumab is a new strategy for the treatment of systemic lupus erythematosus. It could antagonize the activity of all type 1 interferons by binding with type I interferon receptor subunit 1. The aim of our study was to evaluate the safety of anifrolumab in patients with moderate to severe SLE (excluding patients with active severe lupus nephritis or central nervous system lupus).

Methods

Four databases (Embase, Cochrane, PubMed, Web of Science) were systematically searched from inception until December 2021 for randomized controlled trials (RCTs) evaluating the safety of anifrolumab versus placebo in SLE patients. Then, the inci

SUBMITTER: Liu Z 

PROVIDER: S-EPMC9537685 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature